calcium lactate (OMT-111) / MetiMedi Pharma - LARVOL DELTA

A phase IIa study to evaluate the efficacy of OMT-111 in patients with metastatic colorectal cancer resistant to standard therapies (ESSO 2023) - "Three cases were judged as "possibly related" and were classified as adverse drug reactions (ADRs). Conclusions The results of the phase IIa study showed that OMT-111 has a comparable efficacy without severe toxicity for the patients with refractory metastatic colorectal cancer."

Clinical • Metastases • P2a data • Colorectal Cancer • Gastrointestinal Cancer • Oncology • Solid Tumor

OMT-111 for Terminal Stage Solid Tumors (clinicaltrials.gov) - P2; N=78; Not yet recruiting; Sponsor: MetiMedi Pharmaceuticals

Clinical • New P2 trial • Breast Cancer • Gastrointestinal Cancer • Hepatology • Lung Cancer • Oncology • Pancreatic Adenocarcinoma • Pancreatic Cancer • Solid Tumor